GENOMTEC S.A. espi 2023-02-09 19:19

Receipt of the decision on granting patent protection for the invention in the territory of USA.

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wroclaw, Poland, hereby reports that today The Company has learned about a positive decision of the American Patent Office granting the Company patent protection for an invention entitled "A method of detecting genetic material in a biological sample and a device for its implementation". Granting a patent is conditional on the Issuer paying the required official fees for which the Management Board of Genomtec S.A. has agreed.

The invention covers the key technical solutions related to the proprietary contactless heating and temperature detection system developed for POCT platforms, including Genomtec ID.

The Issuer informs that this is the second patent granted by the American Patent Office and the tenth patent received by the Company. The Issuer is pending over twenty patent applications all over the world.

The Issuer's Management Board decided that the receipt of the above patent is confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual and industrial property. Properly secured intellectual and industrial property may constitute the Issuer's competitive advantage - and its safe commercialization is possible provided that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners in the scope of implementing the commercialization strategy.

Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. POCT diagnostics using the Genomtec ID platform is the key area of the Issuer's operations. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR